Benefits and risks of antihypertensive medications in the elderly

Journal of Internal Medicine

Volumn 278, Issue 6, 2015, Pages 599-626

  Butt, D A ^a,b   Harvey, P J ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SCARBOROUGH HOSPITAL   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Antihypertensive medications; Blood pressure; Elderly; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; NITRENDIPINE; THIAZIDE DIURETIC AGENT;

AGING; ANTIHYPERTENSIVE THERAPY; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL STUDY; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; FALL RISK; FRACTURE; GERIATRIC PATIENT; HEART FAILURE; HIP FRACTURE; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; AGED; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; PATHOPHYSIOLOGY; RISK ASSESSMENT;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL DECISION-MAKING; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PHARMACOVIGILANCE; RISK ASSESSMENT;

EID: 84955198451     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12446     Document Type: Review

References (102)

1. Kjeldsen S, Feldman RD, Lisheng L et al. Updated national and international hypertension guidelines: a review of current recommendations. Drugs 2014; 74: 2033-51.
2. Franklin SS, Gustin W, Wong ND et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-15.
3. Mackenzie IS, MacDonald TM. Hypertension in octogenarians - treatment strategies and challenges. Eur Cardiol 2011; 7: 25-8.
4. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994; 23: 275-85.
5. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
6. Daskalopoulou SS, Rabi DM, Zarnke KB et al. The 2015 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015; 31: 549-68.
7. Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens 2011; 24: 135-44.
8. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 2013; 24: 2649-57.
9. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012; 172: 1739-44.
10. Gribbin J, Hubbard R, Gladman J, Smith C, Lewis S. Risk of falls associated with antihypertensive medication: self-controlled case series. Pharmacoepidemiol Drug Saf 2011; 20: 879-84.
11. Gribbin J, Hubbard R, Gladman JR, Smith C, Lewis S. Risk of falls associated with antihypertensive medication: population-based case-control study. Age Ageing 2010; 39: 592-7.
12. Berry SD, Zhu Y, Choi H, Kiel DP, Zhang Y. Diuretic initiation and the acute risk of hip fracture. Osteoporos Int 2013; 24: 689-95.
13. Gueyffier F, Bulpitt C, Boissel JP et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353: 793-6.
14. Bulpitt CJ, Beckett NS, Cooke J et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409-17.
15. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304: 405-12.
16. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.
17. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
18. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64.
19. Amery A, Birkenhager W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54.
20. Wei Y, Jin Z, Shen G et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens 2013; 15: 420-7.
21. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-80.
22. Ekbom T, Linjer E, Hedner T et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004; 13: 137-41.
23. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-75.
24. Bakris G, Briasoulis A, Dahlof B et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 2013; 112: 255-9.
25. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92.
26. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393-8.
27. Ogihara T, Matsuzaki M, Umemoto S et al. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35: 441-8.
28. Mancia G, Brown M, Castaigne A et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41: 431-6.
29. Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48: 385-91.
30. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31: 2115-27.
31. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
32. Ogihara T, Saruta T, Rakugi H et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56: 196-202.
33. Davis BR, Piller LB, Cutler JA et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006; 113: 2201-10.
34. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-6.
35. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.
36. Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C. Treating hypertension in the very elderly-Benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J 2014; 35: 1712-8.
37. Uijen AA, Bakx JC, Mokkink HG, van Weel C. Hypertension patients participating in trials differ in many aspects from patients treated in general practices. J Clin Epidemiol 2007; 60: 330-5.
38. Tinetti ME, Han L, McAvay GJ et al. Anti-hypertensive medications and cardiovascular events in older adults with multiple chronic conditions. PLoS ONE 2014; 9: e90733.
39. Foulquier S, Bohm M, Schmieder R et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. J Hypertens 2014; 32: 1334-41.
40. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.
41. Charpentier MM, Bundeff A. Treating hypertension in the very elderly. Ann Pharmacother 2011; 45: 1138-43.
42. Tulner LR, Kuper IM, van Campen JP et al. Treatment of hypertension in an elderly outpatient population in the Netherlands. Am J Geriatr Pharmacother 2009; 7: 204-9.
43. Angeli F, Reboldi G, Verdecchia P. Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Hypertens Res 2013; 36: 109-11.
44. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-5.
45. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc DrugsTher 2000; 14: 373-9.
46. Fagard RH, Staessen JA, Thijs L et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007; 167: 1884-91.
47. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the argument. Hypertension 2014; 63: 29-36.
48. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Reboldi G. Aggressive blood pressure lowering is dangerous: the J-curve: con side of the argument. Hypertension 2014; 63: 37-40.
49. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54: 1827-34.
50. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010; 31: 2837-40.
51. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53: 1948-52.
52. Skoog I, Lernfelt B, Landahl S et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
53. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-51.
54. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 4: CD004034.
55. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-9.
56. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
57. Trompet S, Westendorp RG, Kamper AM, de Craen AJ. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29: 306-8.
58. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 2008; 30: 744-66.
59. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31: 1073-82.
60. Takeda S, Sato N, Takeuchi D et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-52.
61. Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens 2014; 32: 1945-57.
62. Verhaeverbeke I, Mets T. Drug induced orthostatic hypotension in the elderly. Drug Saf 1997; 17: 105-18.
63. Burton L, Norton M, Newton JL. Are some antihypertensives more prone to induce hypotensive side effects than others? Age Ageing 2004; 33: 626-8.
64. Campese V, Schneider EL. Reevaluating the use of antihypertensive medications, a first step toward reducing polypharmacy in very old patients. J Clin Hypertens 2010; 12: 621-4.
65. Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508-19.
66. Wu JS, Yang YC, Lu FH, Wu CH, Chang CJ. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens Res 2008; 31: 897-904.
67. Fedorowski A, Burri P, Melander O. Orthostatic hypotension in genetically related hypertensive and normotensive individuals. J Hypertens 2009; 27: 976-82.
68. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005; 30: 173-8.
69. Rose KM, Tyroler HA, Nardo CJ et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study. Am J Hypertens 2000; 13: 571-8.
70. Tinetti ME, McAvay GJ, Fried TR et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes. J Am Geriatr Soc 2008; 56: 1409-16.
71. Schoofs M, van der Klift M, Hofman A et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476-82.
72. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999; 47: 40-50.
73. Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-60.
74. Shuto H, Imakyure O, Matsumoto J et al. Medication use as a risk factor for inpatient falls in an acute care hospital: a case-crossover study. Br J Clin Pharmacol 2010; 69: 535-42.
75. Whitaker HJ, Farrington CP, Spiessens B et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768-97.
76. Glanz JM, McClure DL, Xu S et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 2006; 59: 808-18.
77. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53.
78. Callisaya ML, Sharman JE, Close J, Lord SR, Srikanth VK. Greater daily defined dose of antihypertensive medication increases the risk of falls in older people-a population-based study. J Am Geriatr Soc 2014; 62: 1527-33.
79. Ham AC, Swart KM, Enneman AW et al. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging 2014; 31: 917-27.
80. Tinetti ME, Han L, Lee DSH et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014; 174: 588-95.
81. Lipsitz LA, Habtemariam D, Gagnon M et al. Reexamining the Effect of Antihypertensive Medications on Falls in Old Age. Hypertension 2015; 66: 183-9.
82. Wong AK, Lord SR, Sturnieks DL, Delbaere K, Trollor JN, Close JC. Angiotensin system-blocking medications are associated with fewer falls over 12 months in community-dwelling older people. J Am Geriatr Soc 2013; 61: 776-81.
83. Wiens M, Etminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 2006; 260: 350-62.
84. Peters R, Beckett N, Burch L et al. The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing 2010; 39: 609-16.
85. Choi HJ, Park C, Lee YK, Ha YC, Jang S, Shin CS. Risk of fractures in subjects with antihypertensive medications: a nationwide claim study. Int J Cardiol 2015; 184: 62-7.
86. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 2011; 26: 1561-7.
87. Butt DA, Mamdani M, Gomes T et al. Risk of osteoporotic fractures with angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive community-dwelling elderly. J Bone Miner Res 2014; 29: 2483-8.
88. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9.
89. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
90. Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011; 108: 294-301.
91. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013; 173: 1629-37.
92. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065-70.
93. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.
94. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73.
95. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309: 226-30.
96. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7.
97. Kaneto A, Miki E, Kosaka K. Effect of beta and beta2 adrenoreceptor stimulants infused intrapancreatically on glucagon and insulin secretion. Endocrinology 1975; 97: 1166-73.
98. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J 2010; 17: 448-56.
99. Tocci G, Paneni F, Palano F et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens 2011; 24: 582-90.
100. Kaihara M, Nakamura Y, Makino H. Effect of angiotensin II receptor blocker on insulin signaling in skeletal muscle cells. Nihon Rinsho 2002; 60: 1945-8.
101. Uehara M, Kishikawa H, Isami S et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 1994; 37: 300-7.
102. Kobayashi N, Ohno T, Yoshida K et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576-81.